Mandate

Vinge advises M42 on its acquisition of Diaverum from Bridgepoint

May 22, 2023 M&A

Vinge is advising M42, an Abu Dhabi-based tech-enabled healthcare company in connection with is acquisition of Diaverum AB.

M42 is a global tech-enabled healthcare leader operating at the forefront of medical development. Diaverum is currently the world’s third-largest provider of dialysis services, operating across 23 countries, with 440 clinics and over 13,000 employees. The acquisition of Diaverum significantly expands M42’s global geographic footprint, enabling it to introduce relevant healthcare services and healthtech solutions in new markets while further enhancing its renal care offering in the GCC. The transaction, which is subject to customary regulatory approvals, is expected to close later in 2023.

Vinges team consisted of Matthias Pannier, Stina Bengtsson, Christoffer Nordin, Josefin Lanker och Josef Groow.

 

Related

Vinge has advised Orexo in connection with its rights issue

Vinge has advised Orexo AB (publ) in connection with a partially guaranteed rights issue of approximately SEK 250 million before transaction costs, subject to approval by an extraordinary general meeting.
October 09, 2026

Vinge advises Axcel and Accru Partners in connection with the acquisitions of R3 Revisionsbyrå AB, Adrevicor Halland AB, Trevi Revision AB and Adrevicor Stockholm AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of R3 Revisionsbyrå AB, Adrevicor Halland AB, Trevi Revision AB and Adrevicor Stockholm AB.
October 08, 2026

Vinge has advised Folksam Group in connection with two investments in infrastructure funds

Vinge has advised Folksam Group in connection with two investments totalling SEK 7.2 billion in infrastructure funds managed by Copenhagen Infrastructure Partners and Arjun Infrastructure Partners, respectively.
October 08, 2026